Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1985 Oct;62(1):128-35.

Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome

Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome

G Poli et al. Clin Exp Immunol. 1985 Oct.

Abstract

We have investigated 25 intravenous drug abusers with the clinical and laboratory features of lymphadenopathy syndrome (LAS) and 10 AIDS patients for the expression of NK activity. LAS and AIDS patients had low NK cytotoxicity compared to normal donors. The defective NK cytotoxicity was analysed in the eight LAS subjects with most marked depression. NK effectors were identified by morphology (large granular lymphocytes, LGL) and monoclonal antibody-defined surface markers (B73.1, N901, HNK1). LAS patients had normal percentages of LGL and B73.1+ and N901+ cells. with the exception of two subjects with very low frequency of B73.1+ and N901+ cells. The percentage of HNK1+ cells was increased in LAS, probably because of the reactivity of this reagent with a subset of conventional OKT8+ cells, relatively augmented in LAS subjects. Depletion of monocytes did not enhance NK activity consistently. LAS patients had a normal frequency of cells capable of binding K562. In-vitro exposure to interferon beta (natural) or gamma (recombinant) augmented the defective NK activity of LAS subjects. Thus, patients with LAS have defective NK activity that cannot be accounted for by a low frequency of the relevant effector cells or by monocytic suppressors. These observations suggest a functional defect of NK cells at one or more of the post-binding steps required for the completion of killing.

PubMed Disclaimer

References

    1. J Immunol. 1979 Dec;123(6):2861-9 - PubMed
    1. Infection. 1984 Nov-Dec;12(6):372-6 - PubMed
    1. Science. 1981 Oct 2;214(4516):24-30 - PubMed
    1. N Engl J Med. 1981 Dec 10;305(24):1439-44 - PubMed
    1. Br Med J (Clin Res Ed). 1982 Jul 3;285(6334):17-9 - PubMed

Publication types